• MS patients should continue their disease modifying therapy during the pandemic. • Newly diagnosed patients should start disease modifying therapy without delay. • The effect on COVID-19 infection and future vaccination should be considered. • Agents that cause prolonged non-selective lymphopenia are not preferred. • Only severe relapses should be treated preferably with oral steroids at home.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308765 | PMC |
http://dx.doi.org/10.1016/j.jns.2020.117005 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!